Search alternatives:
significantly teer » significantly better (Expand Search), significantly weaker (Expand Search), significantly lower (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
significantly teer » significantly better (Expand Search), significantly weaker (Expand Search), significantly lower (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
-
1261
-
1262
-
1263
-
1264
-
1265
-
1266
-
1267
Data Sheet 1_Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators.pdf
Published 2025“…The data were compared with regard to changes under therapy and with regard to differences between clinical responders and non-responders.</p>Results<p>The initial therapy with methylprednisolone had no significant effect on immunoglobulin levels and (auto)antibody reactivities (n<sub>max</sub>=27 MS patients). …”
-
1268
Data Sheet 1_Metabolic adaptation fluctuates with different prediction equations: a secondary analysis based on a weight-loss clinical trial.docx
Published 2025“…Both Katch-McArdle-determined RMR and BIA-determined RMR presented a significant decrease between baseline and the end of the intervention (week 16). …”
-
1269
Supplementary file 1_Characteristics, clinical evidence and implementation effects of conditional approvals for drugs in China, a pooled analysis from 2020 to 2023.docx
Published 2025“…Notably, a substantial disparity existed in the pivotal premarketing and completed/ongoing postmarketing clinical trial features and endpoints. Additionally, CAs which initiated confirmation clinical trials before the CA application submission were more likely to obtain regular approval. …”
-
1270
Table1_Asparagus officinalis L. extract exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells and a transgenic mouse model of endometrial cancer.pdf
Published 2024“…The metabolites from asparagus officinalis extracts or asparagus officinalis extracts exhibit significant anti-tumorigenic activity in some pre-clinical models of cancer.…”
-
1271
DataSheet1_Asparagus officinalis L. extract exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells and a transgenic mouse model of endometrial cancer.pdf
Published 2024“…The metabolites from asparagus officinalis extracts or asparagus officinalis extracts exhibit significant anti-tumorigenic activity in some pre-clinical models of cancer.…”
-
1272
Table2_Asparagus officinalis L. extract exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells and a transgenic mouse model of endometrial cancer.pdf
Published 2024“…The metabolites from asparagus officinalis extracts or asparagus officinalis extracts exhibit significant anti-tumorigenic activity in some pre-clinical models of cancer.…”
-
1273
DataSheet2_Asparagus officinalis L. extract exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells and a transgenic mouse model of endometrial cancer.pdf
Published 2024“…The metabolites from asparagus officinalis extracts or asparagus officinalis extracts exhibit significant anti-tumorigenic activity in some pre-clinical models of cancer.…”
-
1274
Data Sheet 1_Prevalence of fungal colonization among patients with psoriasis in difficult-to-treat areas: impact of apremilast on mycotic burden and clinical outcomes.pdf
Published 2024“…Finally, improvements in clinical scores i.e., PASI, NAPSI, DLQI, itch VAS, PAIN VAS, scPGA and sPGA-G and biochemical serum profile, as well as a significant decrease in serum IL-17A, TGF-β 1 and IL-10 levels (from 8.51 to 4.16 pg/mL; from 66.10 to 48.70 ng/mL and from 20.05 to 14 pg/mL, respectively) were observed in all patients.…”
-
1275
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
1276
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
1277
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
1278
The flow chart of the study.
Published 2025“…</p><p>Conclusions</p><p>Our study shows that higher HCT in the first 2 hours of life was statistically significant association with decreased ROP and blood transfusion in very preterm infants. …”
-
1279
Baseline characteristics of participants.
Published 2025“…</p><p>Conclusions</p><p>Our study shows that higher HCT in the first 2 hours of life was statistically significant association with decreased ROP and blood transfusion in very preterm infants. …”
-
1280
